(Q35952647)

11 August 2017

1 reference

title

The role of topical calcineurin inhibitors in atopic dermatitis (English)

1 reference

11 August 2017

A Alomar

1

1 reference

11 August 2017

J Berth-Jones

2

1 reference

11 August 2017

J D Bos

3

1 reference

11 August 2017

A Giannetti

4

1 reference

11 August 2017

S Reitamo

5

1 reference

11 August 2017

T Ruzicka

6

1 reference

11 August 2017

J-F Stalder

7

1 reference

11 August 2017

K Thestrup-Pedersen

8

1 reference

11 August 2017

European Working Group on Atopic Dermatitis

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

British Journal of Dermatology

11 August 2017

published in

1 reference

11 August 2017

volume

151 Suppl 70 Dec 2004

1 reference

11 August 2017

page(s)

3-27

1 reference

Quality of life in atopic dermatitis.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

The cost of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Epidemiology of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Atopic dermatitis: new insights and opportunities for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Pathogenesis of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Topical corticosteroid phobia in patients with atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

FK506 inhibition of histamine release and cytokine production by mast cells and basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Pimecrolimus does not affect Langerhans cells in murine epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

First experience of topical SDZ ASM 981 in children with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06269.X

10.1111/J.1365-2133.2004.06269.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference